Why the study?
The molecular pathogenesis of high-grade myxofibrosarcoma remains poorly understood and systemic treatment options for advanced disease are limited.
This review summarizes the current understanding of the biology, diagnosis, and management of high-grade myxofibrosarcoma, highlighting the need for better molecular understanding and systemic treatments.
Offers clinicians updated synthesis for high-grade MFS management; leaves open needs for molecular targets and systemic therapies.
Myxofibrosarcoma (MFS) is one of the most common adult soft tissue sarcomas, typically arising in the extremities. Histologically, MFS is classified into three grades: low, intermediate, and high. Histological grades correlate with distant metastases and tumor-associated mortality. The diagnosis of MFS is challenging due to a lack of well-characterized immunohistochemical markers. High-grade MFS displays highly complex karyotypes with multiple copy number alterations. Recent integrated genomic studies have shown the predominance of somatic copy number aberrations. However, the molecular pathogenesis of high-grade MFS remains poorly understood. The standard treatment for localized MFS is surgical resection. The systemic treatment options for advanced disease are limited. This review provides an updated overview of the clinical and imaging features, pathogenesis, histopathology, and treatment of high-grade MFS.
No takes yet. Share an insight, caveat, or question.
Nishio et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: